2-chloro-5-(1-methyl-1H-pyrazol-3-yl)-N-(1-phenyl-3-pyridin-4-yl-1H-pyrazol-5-yl)-4-(trifluoromethyl)benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-chloro-5-(1-methyl-1H-pyrazol-3-yl)-N-(1-phenyl-3-pyridin-4-yl-1H-pyrazol-5-yl)-4-(trifluoromethyl)benzamide
• 英文别名: 2-chloro-5-(1-methylpyrazol-3-yl)-N-(2-phenyl-5-pyridin-4-ylpyrazol-3-yl)-4-(trifluoromethyl)benzamide
• 化学式: C₂₆H₁₈ClF₃N₆O
• 分子量: 522.9
• InChiKey: YPTJLKAUNVFXEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  77.6
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS DE LA KINASE TRKA, COMPOSITIONS ET MÉTHODES ASSOCIÉES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015143653A1

  公开（公告）日：2015-10-01

  The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

  本发明涉及一种替代的五元杂环芳基苯甲酰胺化合物，化学式为(I)，它们是肌动蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此在治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与失髓鞘形成或脱髓鞘有关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体TrkA的异常活动有关的疾病或紊乱中具有用处。
• TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3122343A2

  公开（公告）日：2017-02-01
• TrKA Kinase Inhibitors, Compositions and Methods Thereof
  申请人：MITCHELL Helen

  公开号：US20170158698A1

  公开（公告）日：2017-06-08

  The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
• US9914736B2
  申请人：——

  公开号：US9914736B2

  公开（公告）日：2018-03-13
• [EN] TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS DE LA KINASE TRKA, COMPOSITIONS EN CONTENANT ET MÉTHODES ASSOCIÉES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015148350A2

  公开（公告）日：2015-10-01

  The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.